Statement: Neutropenia was the most prevalent adverse event in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 9/29 (31.03%)   Neutropenia 5/29 (17.24%)   Cataracts 1/29 (3.45%)   Abdominal Pain 1/29 (3.45%)   Perforated Appendix 1/29 (3.45%)   Surgical Intervention 1/29 (3.45%)   Deep Vein Thrombosis 1/29 (3.45%)   Cerebrovascular Ischemia 1/29 (3.45%) Adverse Events 2: